Bioregenerative technology company FesariusTherapeutics Inc announced on Thursday the publication of its peer reviewed evidence of category leading speed of 'neodermis' formation, which it claims may have the potential to reduce multiple surgical interventions, repetitive product applications, and to significantly reduce the overall burden to the healthcare delivery system versus current standard of care.

'Enhanced Early Vascularization and Tissue Formation in a Biphasic Collagen Hydrogel Dermal Regeneration Template' was published in Wound Repair and Regeneration, a journal in cellular and molecular biology, connective tissue, and biological mediator studies in the field of tissue repair and regeneration. This peer-reviewed evidence offers a head-to-head comparison against the leading dermal template in a porcine animal model and provides further insight into the novel mechanism employed by DermiSphere hDRT, which enables rapid integration and vascularization of the scaffold. Preclinical data suggests that the device could provide a significant benefit to surgeons and their patients suffering from full thickness and deep partial thickness wounds.

DermiSphere hDRT is a proprietary hydrogel dermal regeneration template designed to leverage the body's natural healing cascade to maximum effect. According to the company, preclinical evidence shows that DermiSphere hDRT allows extensive vascularization and complete cell invasion of the dermal template within 3 days, compared to market-leading templates which take significantly longer to achieve.